Literature DB >> 19942704

Decreased diffusivity in the caudate nucleus of presymptomatic huntington disease gene carriers: which explanation?

M L Mandelli1, M Savoiardo, L Minati, C Mariotti, D Aquino, A Erbetta, S Genitrini, S Di Donato, M G Bruzzone, M Grisoli.   

Abstract

BACKGROUND AND
PURPOSE: The neostriatum is known to be affected in HD. In this work, our aim was to determine whether microstructural and volumetric alterations occur in the neostriatum of presymptomatic HD gene carriers and in patients with early-stage HD.
MATERIALS AND METHODS: We studied a group of 15 presymptomatic gene carriers who were far from the estimated symptom onset (16% probability of developing the disease within 5 years), a group of 9 patients with early symptomatic HD, and 2 groups of age-matched controls. Volumetric MR imaging and DWIs were acquired, and statistical analyses were performed on the volumes of the caudate nucleus and putamen and on the corresponding MD measurements.
RESULTS: Neostriatal volumes were significantly smaller in both presymptomatic HD gene carriers and symptomatic patients with respect to controls. However, whereas the diffusivity in the caudate nucleus was increased in the symptomatic patients, it was decreased in the presymptomatic gene carriers.
CONCLUSIONS: Altered diffusivity and reduced volume of the caudate nucleus in presymptomatic HD gene carriers indicate that the neostriatum is affected well before the onset of symptoms. The observed initial decrease and subsequent increase of MD might be related to the combined effect of increased oligodendroglial population, putatively a developmental abnormality, and incipient neurodegeneration.

Entities:  

Mesh:

Year:  2009        PMID: 19942704      PMCID: PMC7964218          DOI: 10.3174/ajnr.A1891

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  27 in total

1.  Quantitative neuropathological changes in presymptomatic Huntington's disease.

Authors:  E Gómez-Tortosa; M E MacDonald; J C Friend; S A Taylor; L J Weiler; L A Cupples; J Srinidhi; J F Gusella; E D Bird; J P Vonsattel; R H Myers
Journal:  Ann Neurol       Date:  2001-01       Impact factor: 10.422

2.  Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain.

Authors:  N Tzourio-Mazoyer; B Landeau; D Papathanassiou; F Crivello; O Etard; N Delcroix; B Mazoyer; M Joliot
Journal:  Neuroimage       Date:  2002-01       Impact factor: 6.556

3.  Echo-planar and gradient-echo diffusion MRI of normal brain iron in the globus pallidus.

Authors:  R N Sener
Journal:  Clin Imaging       Date:  2002 Nov-Dec       Impact factor: 1.605

Review 4.  Diffusion MR imaging: clinical applications.

Authors:  D Le Bihan; R Turner; P Douek; N Patronas
Journal:  AJR Am J Roentgenol       Date:  1992-09       Impact factor: 3.959

5.  Volumetrics of the caudate nucleus: reliability and validity of a new manual tracing protocol.

Authors:  Jeffrey Chee Leong Looi; Olof Lindberg; Benny Liberg; Vanessa Tatham; Rajeev Kumar; Jerome Maller; Ellen Millard; Perminder Sachdev; Göran Högberg; Marco Pagani; Lisa Botes; Eva-Lena Engman; Yi Zhang; Leif Svensson; Lars-Olof Wahlund
Journal:  Psychiatry Res       Date:  2008-07-25       Impact factor: 3.222

6.  Guidelines for the molecular genetics predictive test in Huntington's disease. International Huntington Association (IHA) and the World Federation of Neurology (WFN) Research Group on Huntington's Chorea.

Authors: 
Journal:  Neurology       Date:  1994-08       Impact factor: 9.910

7.  Estimation of the effective self-diffusion tensor from the NMR spin echo.

Authors:  P J Basser; J Mattiello; D LeBihan
Journal:  J Magn Reson B       Date:  1994-03

8.  Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease.

Authors:  Andrea Ciarmiello; Milena Cannella; Secondo Lastoria; Maria Simonelli; Luigi Frati; David C Rubinsztein; Ferdinando Squitieri
Journal:  J Nucl Med       Date:  2006-02       Impact factor: 10.057

9.  Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory.

Authors:  S D Taylor-Robinson; R A Weeks; D J Bryant; J Sargentoni; C D Marcus; A E Harding; D J Brooks
Journal:  Mov Disord       Date:  1996-03       Impact factor: 10.338

10.  Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.

Authors: 
Journal:  Mov Disord       Date:  1996-03       Impact factor: 10.338

View more
  8 in total

1.  Frontal cortex BOLD signal changes in premanifest Huntington disease: a possible fMRI biomarker.

Authors:  Stefania Ferraro; Lorenzo Nanetti; Sylvie Piacentini; Maria L Mandelli; Nicola Bertolino; Francesco Ghielmetti; Francesca Epifani; Anna Nigri; Franco Taroni; Maria G Bruzzone; Stefano Di Donato; Mario Savoiardo; Caterina Mariotti; Marina Grisoli
Journal:  Neurology       Date:  2014-06-04       Impact factor: 9.910

2.  Magnetization transfer MR imaging demonstrates degeneration of the subcortical and cortical gray matter in Huntington disease.

Authors:  A Ginestroni; M Battaglini; S Diciotti; R Della Nave; L N Mazzoni; C Tessa; M Giannelli; S Piacentini; N De Stefano; M Mascalchi
Journal:  AJNR Am J Neuroradiol       Date:  2010-09-02       Impact factor: 3.825

3.  Altered diffusion tensor imaging measurements in aged transgenic Huntington disease rats.

Authors:  Bjørnar T Antonsen; Yi Jiang; Jelle Veraart; Hong Qu; Huu Phuc Nguyen; Jan Sijbers; Stephan von Hörsten; G Allan Johnson; Trygve B Leergaard
Journal:  Brain Struct Funct       Date:  2012-05-23       Impact factor: 3.270

4.  Evaluation of multi-modal, multi-site neuroimaging measures in Huntington's disease: Baseline results from the PADDINGTON study.

Authors:  Nicola Z Hobbs; James H Cole; Ruth E Farmer; Elin M Rees; Helen E Crawford; Ian B Malone; Raymund A C Roos; Reiner Sprengelmeyer; Alexandra Durr; Bernhard Landwehrmeyer; Rachael I Scahill; Sarah J Tabrizi; Chris Frost
Journal:  Neuroimage Clin       Date:  2012-12-09       Impact factor: 4.881

Review 5.  Diffusion imaging in Huntington's disease: comprehensive review.

Authors:  Carlos Estevez-Fraga; Rachael Scahill; Geraint Rees; Sarah J Tabrizi; Sarah Gregory
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-10-08       Impact factor: 10.154

6.  Basal ganglia-cortical structural connectivity in Huntington's disease.

Authors:  Marianne J U Novak; Kiran K Seunarine; Clare R Gibbard; Peter McColgan; Bogdan Draganski; Karl Friston; Chris A Clark; Sarah J Tabrizi
Journal:  Hum Brain Mapp       Date:  2015-01-30       Impact factor: 5.038

7.  Multi-modal neuroimaging in premanifest and early Huntington's disease: 18 month longitudinal data from the IMAGE-HD study.

Authors:  Juan F Domínguez D; Gary F Egan; Marcus A Gray; Govinda R Poudel; Andrew Churchyard; Phyllis Chua; Julie C Stout; Nellie Georgiou-Karistianis
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

8.  Galectin-3 is required for the microglia-mediated brain inflammation in a model of Huntington's disease.

Authors:  Jian Jing Siew; Hui-Mei Chen; Huan-Yuan Chen; Hung-Lin Chen; Chiung-Mei Chen; Bing-Wen Soong; Yih-Ru Wu; Ching-Pang Chang; Yi-Chen Chan; Chun-Hung Lin; Fu-Tong Liu; Yijuang Chern
Journal:  Nat Commun       Date:  2019-08-02       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.